Various cancers treated by paclitaxel. malignant neoplasms
Conditions
Interventions
Intervention 1: Intervention group: In the drug group, starting one day before the paclitaxel injection, three times a day each time in the amount of 5 cc of the oral solution containing the hydroalco
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Suffering from cancer and starting chemotherapy regimen containing paclitaxel at a dose of 175 mg/m2. age between 18-70 yers
Exclusion criteria
Exclusion criteria: Liver failure (due to the change in drug clearance): If the ALT and AST tests are more than two to three times the normal level at the beginning of the treatment, the patient will be excluded from the study. Renal failure (GFR30 Use of other neurotoxic drugs in the chemotherapy regimen, such as platinums or vincristine Suffering from concurrent neuromuscular diseases such as myasthenia gravis Guillain Barre syndrome, multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropathy. Timepoint: at baseline-after each course-at the end of study. Method of measurement: based on NCI-CTC (national cancer institute-common toxicity criteria version 5). | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep assessment. Timepoint: at the beginning of study-at the end of study. Method of measurement: Based on the Pittsburgh Sleep Quality Index.;Assessment of anxiety. Timepoint: at the beginning of study-at the end of study. Method of measurement: Generalized Anxiety Disorder scale questionnaire index. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Elyasi
Mashhad University of Medical Sciences
Outcome results
None listed